Sources Novo Nordisk NDA filing for CagriSema, December 18, 2025 American Diabetes Association REDEFINE-1 and REDEFINE-2 results, ADA 2026 Scientific Sessions HCPLive REDEFINE-1 Phase 3 safety and efficacy data Clinical Trials Arena REDEFINE-4: CagriSema vs tirzepatide head-to-head, February 2026 Life Science Daily News CagriSema FDA review timeline and NDA update, July 2026 PharmExec REDEFINE-1 results: CagriSema falls short of 25% weight loss target Drugs.com CagriSema FDA approval status history New England Journal of Medicine REDEFINE-1 full publication (presented at ADA 2026) Novo Nordisk REIMAGINE Phase 3 diabetes trial results, ADA 2026 and The Lancet FDA Wegovy (semaglutide) prescribing information, 2025 Related reading on Heally: What is Wegovy HD

Jan 11th, 2025 The Future Of Dieting: Personalized Meal Plans Based on AI Artificial intelligence (AI) is revolutionizing diet and nutrition by personalizing meal planning based on individual health data, dietary preferences, and lifestyle habits, addressing the limitations of one-size-fits-all diet approaches
Advances in peptide synthesis and delivery methods are expected to enhance their therapeutic potential further
Persistent thirst, frequent urination, nausea, or mental confusion warrant prompt blood tests for calcium
2b) or when richness and evenness were combined in the ShannonWiener Diversity Index H (Fig
Prescription-Only Medicine (POM): Can only be obtained with a valid prescription from an authorised health professional